mixed EVs with micelles containing polyethylene glycol and EGFR nanobodies for targeting EGFR overexpressing cancer cells.[12] Another strategy involved clicking azide‐modified EVs with dibenzocyclooctyne‐derivatized SIRPα antibodies.[43] Our approach did not involve fusing the antibody sequence directly to EV‐associated proteins or chemical modifications of antibodies, which could have been hampered by the size and complexity of the antibody structure. Here, SIRPA is linked to cancer.